ArticleJournal of pharmaceutical sciences2015
The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants.
Article in Journal of pharmaceutical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Phase-Inversion In Situ Implants for Dental Drug Delivery: A QbD-Guided In Vitro Technological Evaluation.Polymers · 2026Article
- PLGA-Based In Situ-Forming Implants, a Quality by Design Perspective.Pharmaceutics · 2026Review
- First-in-line subcutaneous injectable for reversible, non-hormonal male contraception.Drug delivery and translational research · 2026Article
- Mechanistic Computational Modeling of Implantable, Bioresorbable Drug Release Systems.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.Nature communications · 2022Article
- Effects of Drug Physicochemical Properties on In-Situ Forming Implant Polymer Degradation and Drug Release Kinetics.Pharmaceutics · 2022Article
- Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.Pharmaceutics · 2022Article
- In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Improving Treatment Efficacy of In Situ Forming Implants via Concurrent Delivery of Chemotherapeutic and Chemosensitizer.Scientific reports · 2020Article
- Improving Treatment Efficacy of In Situ Forming Implants via Concurrent Delivery of Chemotherapeutic and Chemosensitizer.Scientific reports · 2020Article
- Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery.Nature communications · 2019Article
- Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Delivery of radix ophiopogonis polysaccharide via sucrose acetateisobutyrate-based in situ forming systems alone or combined with itsmono-PEGylation.Drug delivery · 2018Article
- Predicting in vivo behavior of injectable, in situ-forming drug-delivery systems.Therapeutic delivery · 2017Article
- Macroporous acrylamide phantoms improve prediction of in vivo performance of in situ forming implants.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Phase-sensitive in situ forming implants (ISFI) are a promising platform for the controlled release of therapeutic agents. The simple manufacturing, ease of placement, and diverse payload capacity make these implants an appealing delivery system for a wide range of applications. Tailoring the release profile is paramount for effective treatment of disease. In this study, three innovative formulation modifications were used to control drug release. Specifically, water, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI), and bovine serum albumin (BSA) were incorporated into an ISFI solution containing the small molecular weight mock drug, sodium fluorescein. The effects of these additives on drug release, swelling, phase inversion, erosion, and implant microstructure were evaluated. Diagnostic ultrasound was used to monitor changes in swelling and phase inversion over time noninvasively. Water, DiI, and the combination of BSA/DiI functioned to reduce burst release 47.6%, 76.6%, and 59.0%, respectively. Incorporation of water into the casting solution also enhanced the release of drug during the diffusion period of release by 165.2% relative to the excipient free control. Incorporation of BSA into the polymer solution did not significantly alter the burst release (p < 0.05); however, the onset of degradation facilitated release was delayed relative to the excipient-free control by 5 days. This study demonstrates that the use of excipients provides a facile method to tailor the release profile and degradation rate of implants without changing the polymer or solvent used in the implant formulation, providing fine control of drug dissolution during distinct phases of release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.